TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy post-menopausal female subjects, at least 45 years of age, with confirmed post-menopausal status~* Hysterectomized subjects~* Body Mass Index (BMI) less than or equal to 34.0 kg/m2~* Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history~* An informed consent document signed and dated by the subject~Exclusion Criteria:~* History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease~* Presence or history of deep vein thrombosis or transient ischemic attack~* History of seizure disorder~* Presence or history of glaucoma or increased intraocular pressure~* Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine~* History of substance abuse within 1 year of study~* A positive urine drug screen~* Treatment with an investigational drug within 30 days~* Consumption of grapefruit or grapefruit related citrus fruits~* 12 lead ECG demonstrating QTc \>450 msec at screening~* Pregnant or nursing females~* Use of prescription or nonprescription drugs and dietary supplements~* History of sensitivity to heparin or heparin induced thrombocytopenia~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality~* Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tamoxifen and Desvenlafaxine SR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Ripening Balloon in Induction of Labour at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged 21 - 40 years old~* Singleton pregnancy with no major fetal anomaly~* Planned induction of labour at 37+0 weeks to 41+6 weeks gestation~* Vaginal delivery is appropriate~* Patient able to give informed consent to participate in the trial~Exclusion Criteria:~* Spontaneous labour at start of planned induction~* Bishop score \<6 and cervical dilatation \>=3 cm at start of induction~* Confirmed rupture of membrane~* Abnormal CTG at start of induction~* Caesarean section delivery is indicated~* Scarred uterus such as previous caesarean section~* Malpresentation in labour~* Latex allergy, severe asthma and glaucoma~* Patient withdraw consent to participate in the trial

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Cervical Ripening Balloon (Type: EXPERIMENTAL): Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
- Prostin (Type: ACTIVE_COMPARATOR): Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy of the Paraneoplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Paraneoplastic Disorder~Exclusion Criteria:~* Metastasis (spread) of cancer to brain, History of additional active malignancy other than non-melanoma skin cancer, History of Hepatitis B, Hepatitis C, HIV or Syphilis.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: EXPERIMENTAL): Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- AML with a poor prognosis defined according to the criteria below: LAM First line: Age \<60 years and unfavorable risk according to the 2017 ELN Age\> = 60 years old and intermediate or unfavorable risk according to the ELN 2017 LAM in Relapse: whatever the age~* ECOG \<= 2~* Patient eligible for intensive chemotherapy~* Informed consent~* Liver function tests: transaminases \<3x normal, bilirubin \<1.5X normal~* Creatinine clearance\> 60ml / min~* LVEF\> = 50%~Exclusion Criteria:~* Uncontrolled infection~* Hep B, C, HIV +~* History of diverticulosis / diverticulitis~* No social security or any other scheme~* Pregnant women or patient unable to take contraception(contraceptive pill, abstinence, IUD unauthorized) in case of fertility. A patient who cannot continue contraception for at least 3 months after the last injection of TOCILIZUMAB is not eligible.~* Lactating women~* Minors~* Adults under guardianship, curatorship or legal protection~* Hypersensitivity to one of the active substances or to one of the excipients~* Patients with tuberculosis~* Patients documented with active COVID

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib for Pediatric Adenotonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2-18 years~* Tonsillectomy, or adenotonsillectomy~* No exclusion criteria~Exclusion Criteria:~* Age \< 2yrs and \>18yrs old~* BMI \< 10th or \> 95th percentile~* Serum creatinine (Cr) \> 2 X UNL (upper normal limit)~* Abnormal liver function; namely alanine aminotransferase (ALT) \> 1.5 X UNL, alkaline phosphatase (ALP) \> 5X UNL, total bilirubin \> 2 X UNL~* History of peptic ulcer disease.~* History of bleeding disorders~* History of severe asthma (requiring recent hospital admission or oral corticosteroid therapy)~* Allergy to celecoxib, sulfonamide compounds or NSAIDs~* Patients receiving CYP2C9 inhibitors fluconazole, amiodarone and oxandrolone~* Patients receiving CYP2C9 inducers rifampin and phenobarbital~* Extremes of body mass index (BMI) (age related below10th or above 90th percentile)~* Parents of any participants, irrespective of age, who are unable to read and understand instructions relayed in English or French~* Participant and/or parents of any participants, irrespective of age, who suffer from dementia, psychosis, significant developmental delay or other impairment that would prohibit the understanding and giving of informed consent or assent or the participation in self-care or toxicity reporting

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Celebrex suspension
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-65 years of age, any ethnic group, either sex~2. Diagnostic and Statistical Manual, 4th edition (DSM IV) diagnosis of schizophrenia or schizoaffective disorder~3. Ability to participate fully in the informed consent process, or have a legal guardian able to participate in the informed consent process.~4. Patient cohort enriched for moderate to severe cognitive symptoms (composite Brief Assessment of Cognition in Schizophrenia (BACS) score 0-3 SD below the mean).~5. No change in antipsychotic for 8 weeks or longer. No change in antipsychotic dose for 4 weeks or longer.~6. No change in anticholinergic, benzodiazepine, or mood stabilizer medications for 4 weeks or longer.~7. No anticipated need to alter any of the above medications (antipsychotics, anticholinergics, benzodiazepines, or mood stabilizers) for the 10-week duration of the study.~Exclusion Criteria:~1. Unstable medical illness or neurologic illness (seizures, cerebrovascular accident); history of prostate, breast, uterine, or ovarian cancer.~2. Use of oral contraceptives or other hormonal supplementation such as estrogen.~3. Other concomitant medications for medical conditions will be addressed on a case-by-case base to determine if exclusionary.~4. Active expression of suicidal or homicidal ideation.~5. Comorbid substance dependence (other than nicotine dependence), or presenting symptoms likely substance-induced, as judged by a study physician.~6. Female patients who are pregnant or breast-feeding.~7. Known allergy to study medication.~8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone, clozapine, etc) will be excluded as suggested by the Federal Drug Administration (FDA); patients taking these agents will not be eligible for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pregnenolone
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of MCI defined as abnormal cognition on objective testing in the absence of dementia or significant functional loss.~* Absence of systemic or other neurological disease that may contribute to cognitive impairment or prevent follow-up over two years.~* Able to give written informed consent.~* Age \>/= 60 years of age~* \>/= 7 years of education~Exclusion Criteria:~* Mini mental state examination (MMSE) score \< 24 at baseline~* Clinical dementia rating (CDR) score \> 0.5 at baseline~* Patients who receive regular medication of drugs which may adversely impact cognition (e.g. tricyclic antidepressants, antipsychotics and/or large doses of hypnotics or anxiolytics)~* Existing or history of cancer~* History of severe head trauma, brain surgery or intracranial hematoma with permanent brain lesion~* Lifetime history of major affective disorder, schizophrenia, or schizo-affective disorder~* Contraindications to MRI (Magnetic resonance imaging)~* Relevant history, physical or imaging findings of neurological disease other than MCI and mild depression~* History of severe anaphylactic reaction or high risk of allergic reaction to drugs~* Patient has received another investigational drug in the preceding 14 days

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe sepsis~* Requirement for fluid resuscitation~Exclusion Criteria:~* serum creatinine \> 300µmol/L~* Chronic renal failure~* Anuria lasting more than 4 hours~* Requirement for renal support

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Voluven® Arm (Type: EXPERIMENTAL): None
- 0.9 % NaCl (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects Magnesium Sulfate and Labetalol Infusion on Peripheral Perfusion and Pain in Nasal Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from the patient.~* Age: 21-45 years old.~* Sex: both sex (males or females).~* Physical status: ASA 1\& II.~* BMI = (20-30 kg/m2).~* Type of operations: elective nasal surgeries such as septoplasty, endoscopic sinus surgery and polypectomy.~* Duration of surgery ≤ two hours.~Exclusion Criteria:~* Altered mental state~* Patients on beta blocker or with known history of allergy to study drugs.~* Advanced hepatic, renal, cardiovascular or respiratory diseases.~* Diabetic patients.~* Patients receiving anticoagulants or on pain killers.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Magnesium sulfate infudsion (Type: ACTIVE_COMPARATOR): patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
- Labetalol infusion (Type: ACTIVE_COMPARATOR): will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of rheumatoid arthritis~* Non-respondent or intolerant to non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy~* Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed~Exclusion Criteria:~* Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment~* Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months~* Patients whose first biologic is rituximab, abatacept or anakinra.~* Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight and serum total IgE level within the dosing table range; body weight of 20 to 150 kg and serum total IgE levels of 30 to 1300 IU/mL~* Receiving asthma long-term control medications of high dose ICS (\>200 µg/day FP or equivalent) and two or more controller medications out of LTRA, theophylline, sodium cromoglycate, LABA, or OCSs 12 weeks prior to the run-in period. These medications should be kept stable for 4 weeks prior to the run-in period and during the run-in period (except for management of asthma attacks/exacerbations)~* Having 2 or more asthma exacerbations requiring treatment with a doubling of the maintenance ICS dose for at least 3 days and/or systemic (oral or IV) corticosteroids in the past; one of these exacerbations must have occurred in the previous 12 months, which is documented in the medical record~* Demonstrating inadequately controlled asthma symptoms during the last 14 day run-in period based on the patient diary which meet any of the following:~Asthma symptoms every day; Night-time symptoms in ≥2 out of the last 14 days (missing data to be treated as a day with no symptoms); Limitation of daily activities in ≥2 out of the last 14 days (missing data to be treated as a day with no limitations)~Exclusion Criteria:~* With a history of food or drug related severe anaphylactoid or anaphylactic reaction(s)~* With positive skin reaction to the study drug at the run-in period~* With known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study drug or drug related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin)~* With platelet level ≤ 100,000/µL (100 x 109/L) at the run-in period~* Who are taking intra-muscular depo-steroids within 4 weeks of the run-in period~* Who are taking systemic (oral or IV) corticosteroids for reasons other than asthma within 4 weeks of the run-in period (patients with chronic OCSs use for asthma are allowed)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): Omalizumab treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Heterosexual male in a stable, monogamous, sexual relationship with a female partner for at least 6 months~* onset of orgasm and ejaculation occurs with minimal sexual stimulation before or shortly after penetration and before the person wishes it~* premature ejaculation (PE) in the majority of intercourse experiences in the 6 months before study initiation~* intravaginal latency ejaculatory time (IELT) of \<=2 minutes in at least 3 out of 4 events~* participants with partners of child-bearing potential must consent to use a medically acceptable method of contraception throughout the entire study~* participant's partner must have a negative pregnancy test at time of screening.~Exclusion Criteria:~* History of surgery or injury to the pelvis or spinal cord, chronic inflammation of the prostate or urethra~* taking medications that are contraindicated for participation in the study~* currently using other forms of therapy for treatment of PE (for example, behavioral therapy or medications applied locally)~* previously participated in a drug study involving dapoxetine or in another drug trial within the last month~* taken pimozide, astemizole, or monoamine oxidase inhibitors within 6 months of the start of the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ABRA Abdominal Closure System in Open Abdomen Management

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ages of 18 and 70~2. patients deemed not a candidate for primary fascial closure at the second laparotomy.~Exclusion Criteria:~1. High risk for imminent death, as determined by the attending surgeon and PI~2. Pre-existing large ventral hernia~3. Significant loss of abdominal wall fascia as a result of trauma or infection~4. Known Crohn's disease~5. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 ABRA plus KCI ABThera or KCI VAC (Type: ACTIVE_COMPARATOR): ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
- KCI V.A.C. Therapy or ABThera Alone (Type: ACTIVE_COMPARATOR): KCI V.A.C. Therapy ABThera Alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete